Protalix Projects Elfabrio to Capture 15-20% Fabry Market Share by 2031

Protalix Pharmaceuticals indicated that its drug Elfabrio is on track to achieve a 15% to 20% market share in the Fabry disease treatment market by 2031, supported by its recent European approval for every-4-weeks administration.